Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-11-12

FDA Approved: LUPRON DEPOT-PED — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for LUPRON DEPOT-PED (leuprolide acetate) by AbbVie, updating its labeling for pediatric use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LUPRON DEPOT-PED (Leuprolide acetate)

Snippet

SUPPL AP for LUPRON DEPOT-PED (LEUPROLIDE ACETATE)